- Home
- ARVN vs ATAI Comparison
ARVN vs ATAI Comparison
Compare ARVN & ATAI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ARVN
- ATAI
- Stock Information
- Founded
- ARVN 2015
- ATAI 2018
- Country
- ARVN United States
- ATAI Germany
- Employees
- ARVN N/A
- ATAI N/A
- Industry
- ARVN Biotechnology: Pharmaceutical Preparations
- ATAI Biotechnology: Pharmaceutical Preparations
- Sector
- ARVN Health Care
- ATAI Health Care
- Exchange
- ARVN Nasdaq
- ATAI Nasdaq
- Market Cap
- ARVN 456.2M
- ATAI 444.7M
- IPO Year
- ARVN 2018
- ATAI 2021
- Fundamental
- Price
- ARVN $7.61
- ATAI $4.61
- Analyst Decision
- ARVN Buy
- ATAI Strong Buy
- Analyst Count
- ARVN 22
- ATAI 3
- Target Price
- ARVN $20.02
- ATAI $13.33
- AVG Volume (30 Days)
- ARVN 1.3M
- ATAI 4.7M
- Earning Date
- ARVN 10-29-2025
- ATAI 11-12-2025
- Dividend Yield
- ARVN N/A
- ATAI N/A
- EPS Growth
- ARVN N/A
- ATAI N/A
- EPS
- ARVN N/A
- ATAI N/A
- Revenue
- ARVN $372,800,000.00
- ATAI $2,309,000.00
- Revenue This Year
- ARVN $1.61
- ATAI $712.99
- Revenue Next Year
- ARVN N/A
- ATAI N/A
- P/E Ratio
- ARVN N/A
- ATAI N/A
- Revenue Growth
- ARVN 299.57
- ATAI 510.85
- 52 Week Low
- ARVN $5.90
- ATAI $1.03
- 52 Week High
- ARVN $29.61
- ATAI $5.34
- Technical
- Relative Strength Index (RSI)
- ARVN 49.90
- ATAI 57.88
- Support Level
- ARVN $7.58
- ATAI $4.50
- Resistance Level
- ARVN $7.89
- ATAI $4.75
- Average True Range (ATR)
- ARVN 0.37
- ATAI 0.28
- MACD
- ARVN -0.03
- ATAI -0.04
- Stochastic Oscillator
- ARVN 18.42
- ATAI 50.33
About ARVN Arvinas Inc.
Arvinas Inc is a United States-based biopharmaceutical company focused on improving the lives of patients suffering from debilitating and life-threatening diseases through the discovery, development and commercialization of therapies that degrade disease-causing proteins.. The company's proprietary Proteolysis-Targeting Chimera (PROTAC), work by inducing the cell's own ubiquitin-proteasome system to target, degrade and remove disease-causing proteins. The group's product candidates are bavdegalutamide, ARV-471 and ARV-766.
About ATAI ATAI Life Sciences N.V.
ATAI Life Sciences NV is a clinical-stage biopharmaceutical company on a mission to develop effective mental health treatments to transform patient outcomes. The company's pipeline of psychedelic-based therapies includes VLS-01 (buccal film DMT) for treatment-resistant depression (TRD) and EMP-01 (oral R-MDMA) for social anxiety disorder. It is also advancing a drug discovery program to identify novel, non-hallucinogenic 5-HT2AR agonists for TRD.